Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Master Protocol Workshop
Session 3: Lessons Learned from Ongoing Master Protocol Platform Trial
Session Chair(s)
Michelle Detry, PhD
- Director, Adaptive Trial Execution & Senior Statistical Scientist
- Berry Consultants LLC, United States
AnnCatherine M. Downing, PharmD
- Senior Research Advisor - Clinical
- Eli Lilly and Company, United States
This session will present lessons learned from a newly initiated Master Protocol Trial regarding strategy and design choice, operational challenges and disclosure considerations, and the role of patients and advocacy groups in the platform trial development. This session will feature the experiences from the newly initiated HEALEY ALS (Amyotrophic Lateral Sclerosis) Platform Trial.
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss the rationale for choosing a Master Protocol Platform Trial design and key design features
- Identify the unique operational challenges and disclosure considerations required for implementing a Master Protocol Platform Trial
- Summarize the role of patient and advocacy groups and perspective towards Master Protocol Platform Trials
Speaker(s)
Speaker
Sabrina Paganoni, MD, PhD
- Assistant Professor
- Harvard Medical School, Healey Center for ALS at Mass General, United States
Speaker
Marianne K Chase
- Senior Director of Clinical Trial Operations
- Neurological Clinical Research Institute, Massachusetts General Hospital, United States
Panelist
Philip John Green
- ALS Patient Advocate
- HEALEY ALS Platform Trial Patient Advisory Committee, United States
Panelist
Sundeep Surendra Sethi, MD, MBA
- Vice President, Safety Operations
- AbbVie, Inc., United States
Panelist
Stephen Finger, PhD
- ALS Patient Advocate
- HEALEY ALS Platform Trial Patient Advisory Committee, United States
